최소 단어 이상 선택하여야 합니다.
최대 10 단어까지만 선택 가능합니다.
다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기Cancer discovery, v.2 no.3, 2012년, pp.270 - 287
Sennino, Barbara , Ishiguro-Oonuma, Toshina , Wei, Ying , Naylor, Ryan M. , Williamson, Casey W. , Bhagwandin, Vikash , Tabruyn, Sebastien P. , You, Weon-Kyoo , Chapman, Harold A. , Christensen, James G. , Aftab, Dana T. , McDonald, Donald M.
AbstractInvasion and metastasis increase after the inhibition of VEGF signaling in some preclinical tumor models. In the present study we asked whether selective VEGF inhibition is sufficient to increase invasion and metastasis and whether selective c-Met inhibition is sufficient to block this effec...
Nature Ferrara 438 967 2005 10.1038/nature04483 Angiogenesis as a therapeutic target
Nat Rev Cancer Ellis 8 579 2008 10.1038/nrc2403 VEGF-targeted therapy: mechanisms of anti-tumour activity
Neoplasia Rubenstein 2 306 2000 10.1038/sj.neo.7900102 Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption
Cancer Cell Casanovas 8 299 2005 10.1016/j.ccr.2005.09.005 Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors
Cancer Cell Ebos 15 232 2009 10.1016/j.ccr.2009.01.021 et al. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis
Cancer Cell Paez-Ribes 15 220 2009 10.1016/j.ccr.2009.01.027 Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis
Nature Bottaro 423 593 2003 10.1038/423593a Cancer: out of air is not out of action
Cancer Cell Pennacchietti 3 347 2003 10.1016/S1535-6108(03)00085-0 Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene
J Cell Physiol Benvenuti 213 316 2007 10.1002/jcp.21183 The MET receptor tyrosine kinase in invasion and metastasis
Nat Rev Mol Cell Biol Trusolino 11 834 2010 10.1038/nrm3012 MET signalling: principles and functions in development, organ regeneration and cancer
Proc Natl Acad Sci U S A Graveel 106 12909 2009 10.1073/pnas.0810403106 Met induces diverse mammary carcinomas in mice and is associated with human basal breast cancer
Proc Natl Acad Sci U S A Ponzo 106 12903 2009 10.1073/pnas.0810402106 Met induces mammary tumors with diverse histologies and is associated with poor outcome and human basal breast cancer
Cancer Ghoussoub 82 1513 1998 10.1002/(SICI)1097-0142(19980415)82:8<1513::AID-CNCR13>3.0.CO;2-7 Expression of c-met is a strong independent prognostic factor in breast carcinoma
Cancer Kong 115 140 2009 10.1002/cncr.23972 Prognostic significance of c-Met expression in glioblastomas
Cancer Res Sawada 67 1670 2007 10.1158/0008-5472.CAN-06-1147 c-Met overexpression is a prognostic factor in ovarian cancer and an effective target for inhibition of peritoneal dissemination and invasion
Int J Cancer Lengyel 113 678 2005 10.1002/ijc.20598 C-Met overexpression in node-positive breast cancer identifies patients with poor clinical outcome independent of Her2/neu
Trends Cell Biol Lai 19 542 2009 10.1016/j.tcb.2009.07.002 Crosstalk in Met receptor oncogenesis
Oncogene Xu 29 2616 2010 10.1038/onc.2010.16 Epidermal growth factor receptor regulates MET levels and invasiveness through hypoxia-inducible factor-1alpha in non-small cell lung cancer cells
Cancer Res You 71 4758 2011 10.1158/0008-5472.CAN-10-2527 VEGF and c-Met blockade amplify angiogenesis inhibition in pancreatic islet cancer
Proc Natl Acad Sci U S A Cullen 108 5759 2011 10.1073/pnas.1017192108 GPR124, an orphan G protein-coupled receptor, is required for CNS-specific vascularization and establishment of the blood-brain barrier
Biochemistry Timofeevski 48 5339 2009 10.1021/bi900438w Enzymatic characterization of c-Met receptor tyrosine kinase oncogenic mutants and kinetic studies with aminopyridine and triazolopyrazine inhibitors
Mol Cancer Res Fleming 3 413 2005 10.1158/1541-7786.MCR-04-0206 Molecular consequences of silencing mutant K-ras in pancreatic cancer cells: justification for K-ras-directed therapy
Int J Cancer Qian 104 542 2003 10.1002/ijc.10997 Radiation stimulates HGF receptor/c-Met expression that leads to amplifying cellular response to HGF stimulation via upregulated receptor tyrosine phosphorylation and MAP kinase activity in pancreatic cancer cells
Nature Hanahan 315 115 1985 10.1038/315115a0 Heritable formation of pancreatic beta-cell tumours in transgenic mice expressing recombinant insulin/simian virus 40 oncogenes
Science Bergers 284 808 1999 10.1126/science.284.5415.808 Effects of angiogenesis inhibitors on multistage carcinogenesis in mice
Int J Cancer Beck 118 2639 2006 10.1002/ijc.21684 Combination of a monoclonal anti-phosphatidylserine antibody with gemcitabine strongly inhibits the growth and metastasis of orthotopic pancreatic tumors in mice
Ann Oncol Christensen 18 Suppl 10 x3 2007 10.1093/annonc/mdm408 A preclinical review of sunitinib, a multitargeted receptor tyrosine kinase inhibitor with anti-angiogenic and antitumour activities
J Bone Miner Res Sampson 26 1283 2011 10.1002/jbmr.336 The orally bioavailable met inhibitor PF-2341066 inhibits osteosarcoma growth and osteolysis/matrix production in a xenograft model
Oncogene Dulak 30 3625 2011 10.1038/onc.2011.84 HGF-independent potentiation of EGFR action by c-Met
J Clin Oncol Kurzrock 29 2660 2011 10.1200/JCO.2010.32.4145 Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer
J Clin Oncol Hussain 29 2011 10.1200/jco.2011.29.15_suppl.4516 Cabozantinib (XL184) in metastatic castration-resistant prostate cancer (mCRPC): Results from a phase II randomized discontinuation trial
Mol Cancer Ther Yakes 10 2298 2011 10.1158/1535-7163.MCT-11-0264 Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth
Gastroenterology Li 141 2218 2011 10.1053/j.gastro.2011.08.009 c-Met is a marker of pancreatic cancer stem cells and therapeutic target
Am J Pathol Inai 165 35 2004 10.1016/S0002-9440(10)63273-7 Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts
Mol Cancer Ther Christensen 6 3314 2007 10.1158/1535-7163.MCT-07-0365 Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma
J Surg Res Bloomston 102 39 2002 10.1006/jsre.2001.6318 TIMP-1 overexpression in pancreatic cancer attenuates tumor growth, decreases implantation and metastasis, and inhibits angiogenesis
Mol Pharmacol Gaspar 72 152 2007 10.1124/mol.106.029025 Inhibition of transforming growth factor beta signaling reduces pancreatic adenocarcinoma growth and invasiveness
Cancer Bruns 89 488 2000 10.1002/1097-0142(20000801)89:3<488::AID-CNCR3>3.0.CO;2-X Vascular endothelial growth factor is an in vivo survival factor for tumor endothelium in a murine model of colorectal carcinoma liver metastases
Nature Pouyssegur 441 437 2006 10.1038/nature04871 Hypoxia signalling in cancer and approaches to enforce tumour regression
J Cell Biol Wang 153 1023 2001 10.1083/jcb.153.5.1023 Activation of the Met receptor by cell attachment induces and sustains hepatocellular carcinomas in transgenic mice
Cancer Res Yu 62 2951 2002 Constitutive c-Met signaling through a nonautocrine mechanism promotes metastasis in a transgenic transplantation model
J Biol Chem Jo 275 8806 2000 10.1074/jbc.275.12.8806 Cross-talk between epidermal growth factor receptor and c-Met signal pathways in transformed cells
Proc Natl Acad Sci U S A Wang 93 8425 1996 10.1073/pnas.93.16.8425 Cellular adherence elicits ligand-independent activation of the Met cell-surface receptor
Cancer Res McDermott 70 1625 2010 10.1158/0008-5472.CAN-09-3620 Acquired resistance of non-small cell lung cancer cells to MET kinase inhibition is mediated by a switch to epidermal growth factor receptor dependency
Cancer Res Qi 71 1081 2011 10.1158/0008-5472.CAN-10-1623 Multiple mutations and bypass mechanisms can contribute to development of acquired resistance to MET inhibitors
Cancer Cell Lopez 1 339 2002 10.1016/S1535-6108(02)00055-7 Elevated levels of IGF-1 receptor convey invasive and metastatic capability in a mouse model of pancreatic islet tumorigenesis
Nat Rev Cancer Bergers 8 592 2008 10.1038/nrc2442 Modes of resistance to anti-angiogenic therapy
Proc Natl Acad Sci U S A Chun 107 17268 2010 10.1073/pnas.1012705107 Polymorphic genetic control of tumor invasion in a mouse model of pancreatic neuroendocrine carcinogenesis
Clin Sci (Lond) Santibanez 121 233 2011 10.1042/CS20110086 TGF-beta/TGF-beta receptor system and its role in physiological and pathological conditions
Oncogene Moghul 9 2045 1994 Modulation of c-MET proto-oncogene (HGF receptor) mRNA abundance by cytokines and hormones: evidence for rapid decay of the 8 kb c-MET transcript
Mol Cancer Res Cheng 6 1521 2008 10.1158/1541-7786.MCR-07-2203 Transforming growth factor-beta signaling-deficient fibroblasts enhance hepatocyte growth factor signaling in mammary carcinoma cells to promote scattering and invasion
Nature Perl 392 190 1998 10.1038/32433 A causal role for E-cadherin in the transition from adenoma to carcinoma
Nat Rev Cancer Thiery 2 442 2002 10.1038/nrc822 Epithelial-mesenchymal transitions in tumour progression
Cancer Metastasis Rev Yilmaz 28 15 2009 10.1007/s10555-008-9169-0 EMT, the cytoskeleton, and cancer cell invasion
Nat Rev Mol Cell Biol Nieto 3 155 2002 10.1038/nrm757 The snail superfamily of zinc-finger transcription factors
J Neurosurg Narayana 110 173 2009 10.3171/2008.4.17492 Antiangiogenic therapy using bevacizumab in recurrent high-grade glioma: impact on local control and patient survival
Cancer Cell Michieli 6 61 2004 10.1016/j.ccr.2004.05.032 Targeting the tumor and its microenvironment by a dual-function decoy Met receptor
Clin Cancer Res Peruzzi 12 3657 2006 10.1158/1078-0432.CCR-06-0818 Targeting the c-Met signaling pathway in cancer
Cancer Res Jin 68 4360 2008 10.1158/0008-5472.CAN-07-5960 MetMAb, the one-armed 5D5 anti-c-Met antibody, inhibits orthotopic pancreatic tumor growth and improves survival
Proc Natl Acad Sci U S A Gjerdrum 107 1124 2010 10.1073/pnas.0909333107 Axl is an essential epithelial-to-mesenchymal transition-induced regulator of breast cancer metastasis and patient survival
Cancer Res Qian 69 8009 2009 10.1158/0008-5472.CAN-08-4889 Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases
Cancer Sci Nakagawa 101 210 2010 10.1111/j.1349-7006.2009.01343.x E7050: a dual c-Met and VEGFR-2 tyrosine kinase inhibitor promotes tumor regression and prolongs survival in mouse xenograft models
Biol Cell Sulpice 101 525 2009 10.1042/BC20080221 Cross-talk between the VEGF-A and HGF signalling pathways in endothelial cells
Am J Pathol Dai 167 429 2005 10.1016/S0002-9440(10)62987-2 Beta-cell-specific ablation of the hepatocyte growth factor receptor results in reduced islet size, impaired insulin secretion, and glucose intolerance
*원문 PDF 파일 및 링크정보가 존재하지 않을 경우 KISTI DDS 시스템에서 제공하는 원문복사서비스를 사용할 수 있습니다.
출판사/학술단체 등이 한시적으로 특별한 프로모션 또는 일정기간 경과 후 접근을 허용하여, 출판사/학술단체 등의 사이트에서 이용 가능한 논문
※ AI-Helper는 부적절한 답변을 할 수 있습니다.